They are not a substitute for a provider's individualized assessment
Oct 27: Coherus BioSciences and Shanghai Junshi Biosciences won approval Friday for Loqtorzi (toripalimab-tpzi)in combination with cisplatin and gemcitabinefor the first-line treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC)
Purpose-built for physicians Combined GLP-1/amylin analog bests monotherapy for HbA1c drop, weight loss in diabetes Key takeaways: Combination cagrilintide and semaglutide conferred a 15.6% weight loss at 32 weeks in type 2 diabetes
Studies suggest that physical activity can raise GLP-1 to levels that remain even after 24 hours have passed
This article highlights the importance of knowing your specific Kaiser Permanente plan details and the evolving criteria that could affect coverage, especially with upcoming changes set for January 1, 2025
Always discuss genetic findings, test results, symptoms, and treatment decisions with your healthcare provider or an allergist to determine appropriate care for your situation